These 5 NASDAQ Stocks Just Hit Their 52-Week Highs

Itron Inc. (NASDAQ:ITRI)’s stock has had a solid performance so far this year, having returned over 46% and was boosted towards a 52-week high of $54.49 after the company reported better-than-expected results for the second quarter at the beginning of September. Both EPS of $0.65 and revenue of $513.02 million soundly beat the consensus estimates of $0.43 in EPS on revenue of $478.7 million. At the end of June, 16 funds we track at Insider Monkey were long Itron, unchanged over the quarter. However, the aggregate value of their holdings went up to to $328.32 million from $324.24 million during the second quarter and represented 20.10% of Itron’s outstanding shares.

NetEase Inc. (ADR) (NASDAQ:NTES) hit a 52-week high of $240.47 at the beginning of the week and is up by around 12% over the last month. In August, NetEase also reported its financial results for the second quarter, which included net revenue of approximately $1.35 billion, which surged by over 83% on the year and topped the estimates by $90 million. The company also posted EPS of $3.67, higher than the expected $2.61. Among the funds we track at Insider Monkey, 27 held $2.8 billion worth of NetEase shares at the end of the June quarter, compared to 31 funds holding $2.27 billion worth of shares a quarter earlier.

Seattle Genetics Inc. (NASDAQ:SGEN) has recently climbed to a 52-week high of $51.98. Last month, Seattle Genetics and Takeda Pharmaceutical announced that the Phase 3 clinical trial evaluating ADCETRIS in patients with cutaneous T-cell lymphoma (CTCL) was successful  and met the primary endpoint of statistically significant improvement in the rate of objective response lasting at least four months (ORR4). At the end of the June quarter, 20 of the funds we track held $1.90 billion worth of Seattle Genetics shares, which translated into 33.70% of the outstanding shares. This compares with 12 funds that reported $1.58 billion worth of stock as of the end of June.

Disclosure: none